Everything below concerns Certificate of analysis. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-07-03. Numbers and descriptions here follow the published literature rather than marketing material.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It is described in the literature as an analogue of the ACTH(4–10) fragment, a short N-terminal portion of adrenocorticotropic hormone that retains some neurotropic activity without the full hormonal effects of the parent peptide. The molecule carries a methionine residue at the N-terminus and two proline residues near the C-terminus, features that shape both its interactions with receptor systems and its chemical stability. The free peptide corresponds to the formula C37H51N9O10S and a molecular mass near 813.9 Da.
The compound was developed in the 1980s at the Institute of Molecular Genetics in Moscow, where it emerged from research on short ACTH fragments and their effects on the central nervous system. Russian pharmaceutical listings describe it as a nootropic and neuroprotective agent, most often formulated as nasal drops. It is not a marketed medicine in the United States or the European Union, and no pharmacopoeial monograph covers it. Consequently, most published clinical experience with the substance originates from a small number of research centres, mainly in Russia and neighbouring countries.
Pharmacological accounts link semax to melanocortin signalling and to modulation of neurotrophic factor expression, particularly brain-derived neurotrophic factor and nerve growth factor. Much of this evidence comes from rodent studies using intranasal delivery, a route chosen because it allows peptides to reach the central nervous system with limited systemic exposure. Whether the same mechanisms operate in humans at comparable magnitude remains an open question. The precise receptor or receptors responsible for the reported behavioural and neuroprotective effects have not been conclusively identified.
Proposed mechanisms center on neurotrophic signaling rather than on classical melanocortin receptor activation. Rodent experiments have reported shifts in the expression of brain-derived neurotrophic factor and nerve growth factor after administration, together with changes in the associated receptor systems. Several authors argue that the peptide acts largely through its degradation products and their interaction with peptidergic pathways, but this remains a hypothesis rather than a settled finding. No single molecular target has been identified in a way that the field broadly accepts.
Published research covers ischemic stroke, traumatic brain injury, cognitive impairment, optic nerve conditions and attention-related measures. Much of the human evidence comes from small trials conducted in one country, which limits how far the results generalize. Animal models supply the larger share of the data, and effects seen in rodents do not transfer automatically to people. Reviews have noted that methodological reporting is often incomplete, making it difficult to pool results or compare treatment schedules across studies.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C37H51N9O10S | Free acid form of the heptapeptide; depends on terminal groups |
| Molecular mass | About 813.9 g/mol | Average mass used for mass spectrometry confirmation |
| Appearance | White to off-white solid | Supplied as a lyophilised powder; hygroscopic |
| Solubility class | Freely soluble in aqueous media | Water, saline, and phosphate buffers; limited organic solubility |
| Typical storage temperature | -20 degrees Celsius | Long term and dry; short working periods may use 2 to 8 degrees Celsius |
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. Its design combines the ACTH(4-7) core fragment with a C-terminal Pro-Gly-Pro extension, a modification intended to improve stability and prolong activity. The molecule is hydrophilic, carries no lipid chains or glycosylation, and has a theoretical mass just over 810 daltons in its free form. All seven residues are proteinogenic amino acids, so no non-natural building blocks appear in the backbone. A free N-terminal methionine and C-terminal proline define the unmodified parent peptide.
The compound was developed during the 1980s at the Institute of Molecular Genetics in Moscow as part of research on fragments of adrenocorticotropic hormone. Early work examined short ACTH-derived sequences that retained neurotrophic effects while lacking the endocrine activity of the full hormone. Semax entered clinical use in Russia during the 1990s, where it received registration for several neurological indications. Outside that region it remained primarily a laboratory research material rather than an approved therapeutic. English-language literature on it grew more slowly and frequently cited the original Russian studies.
Identity and purity of semax are established with reversed-phase high-performance liquid chromatography coupled to ultraviolet detection, usually at 214 nanometres. Mass spectrometry, most often electrospray ionisation in positive mode, confirms the molecular mass and reveals truncated sequences. Amino acid analysis and peptide mapping after enzymatic digestion provide additional structural confirmation. Laboratories typically report purity as the percentage area of the main peak, a figure that does not capture isomeric or oxidised variants unless the method resolves them.
The peptide is prone to several degradation pathways. Oxidation of the methionine residue produces a sulfoxide that elutes close to the parent peak in many chromatographic systems. Hydrolysis of peptide bonds and deamidation of susceptible residues in related sequences also reduce purity over time. Lyophilised material kept dry at minus twenty degrees Celsius and shielded from light is the most stable form commonly described in laboratory practice.
The C-terminal Pro-Gly-Pro extension is not incidental. Proline-rich tails are known to resist several common peptidases, and the published literature attributes the longer half-life of Semax, relative to unmodified ACTH fragments, to this feature. The modification also removes the melanocyte-stimulating and corticosteroidogenic activity that characterizes longer ACTH-derived sequences. Because the molecule is small and hydrophilic, it is typically formulated as an aqueous solution for intranasal or parenteral delivery. Acetylation or amidation at the termini appears in closely related research peptides and shifts the mass by a fixed increment.
Reported pharmacological work centers on neurotrophic signaling, including changes in BDNF and NGF expression in hippocampal tissue in animal models. Human data come largely from studies conducted in Russia, and how well those results generalize to other populations remains an open question. Regulatory status differs sharply by jurisdiction: Semax is a registered prescription medicine in Russia, while it holds no approved marketing status in the United States or the European Union. Outside such jurisdictions it is generally handled as a research chemical, which affects both documentation and quality expectations.
=== Medications === Medications for PMOS include metformin and oral contraceptives. Metformin is a medication commonly used in type 2 diabetes, and is used frequently off-label in the management of PMOS. It is recommended for those with a BMI over 25 to treat insulin resistance and normalise lipid profiles, and can also be considered for the treatment of irregular periods in adolescents and for those with a BMI under 25. Metformin is associated with several side effects, including abdominal pain, metallic taste in the mouth, diarrhoea and vomiting. It can also be used to help women get pregnant, but it is not the most effective drug for it. Combined oral contraceptives (COCs) can be used to reduce the symptoms of hirsutism and regulate menstrual periods. They increase sex hormone binding globulin production, and reduce levels of androgens. A regular cycle reduces the risk of endometrial cancer. Contraceptive pills with only progestogens can be used to improve menstrual regularity, but not for symptoms of androgen excess. Antiandrogens such as finasteride and flutamide do not show advantages over COCs for treating hirsutism, but can be an option for people for whom COCs are contraindicated or who do not tolerate them. It may take six to twelve months for COCs to be effective for hirsutism. For the treatment of androgenic alopecia, a combination of antiandrogens and combined oral contraceptives can be tried, but it is difficult to treat. GLP-1 receptor agonists, such as liraglutide and semaglutide, may be more effective than metformin alone at metabolic improvements.
Heparin-binding EGF-like growth factor (HB-EGF) transforming growth factor-α (TGF-α) Amphiregulin (AR) Epiregulin (EPR) Epigen Betacellulin (BTC) neuregulin-1 (NRG1) neuregulin-2 (NRG2) neuregulin-3 (NRG3) neuregulin-4 (NRG4). All family members contain one or more repeats of the conserved amino acid sequence: CX7CX4-5CX10-13CXCX8GXRC Where C is cysteine, G is glycine, R is arginine, and X represents any amino acid. This sequence contains six cysteine residues that form three intramolecular disulfide bonds. Disulfide bond formation generates three structural loops that are essential for high-affinity binding between members of the EGF-family and their cell-surface receptors.
=== Fashions === The term "glabrousness" also has been applied to human fashions, wherein some participate in culturally motivated hair removal by depilation (surface removal by shaving, dissolving), or epilation (removal of the entire hair, such as waxing or plucking). Although the appearance of secondary hair on parts of the human body commonly occurs during puberty, and therefore, is often seen as a symbol of adulthood, removal of this and other hair may become fashionable in some cultures and subcultures. In many modern Western cultures, men are encouraged to shave their beards, and women are encouraged to remove hair growth in various areas. Commonly depilated areas for women are the underarms, legs, and pubic hair. Some individuals depilate the forearms. In recent years, bodily depilation in men has increased in popularity among some subcultures of Western men. For men, the practice of depilating the pubic area is common, especially for aesthetic reasons. Most men will use a razor to shave this area, however, as best practice, it is recommended to use a body trimmer to shorten the length of the hair before shaving it off completely.
Sources: en.wikipedia.org
==== Theory of mind network and default mode network ==== Psychedelics, including psilocybin, have been shown to affect different clusters of brain regions known as the "theory of mind network" (ToMN) and the default mode network (DMN). The ToMN involves making inferences and understanding social situations based on patterns, whereas the DMN relates more to introspection and one's sense of self. The DMN, in particular, is related to increased rumination and worsening self-image in patients with major depressive disorder (MDD). In studies done with single use psilocybin, areas of the DMN showed decreased functional connectivity (communication between areas of the brain). This finding provides functional insight into the work of psilocybin in increasing one's sense of connection to one's surroundings, as the areas of the brain involved in introspection decrease in functionality under the effects of the drug. Conversely, areas of the brain involved in the ToMN showed increased activity and functional activation in response to psychedelics. These results were not unique to psilocybin and there was no significant difference in brain activation found in similar trials of mescaline and LSD. Information and studies into the DMN and ToMN are relatively sparse and their connections to other psychiatric illnesses and the use of psychedelics is still largely unknown.
== External links == The MEROPS online database for peptidases and their inhibitors: S01.233 Archived 2019-09-13 at the Wayback Machine Plasmin at the U.S. National Library of Medicine Medical Subject Headings (MeSH) This article incorporates text from the United States National Library of Medicine, which is in the public domain.
Hurricane Katrina struck early in Bush's second term and was one of the most damaging natural disasters in U.S. history. Katrina formed in late August during the 2005 Atlantic hurricane season and devastated much of the north-central Gulf Coast of the United States, particularly New Orleans. Bush declared a state of emergency in Louisiana on August 27 and in Mississippi and Alabama the following day. The eye of the hurricane made landfall on August 29, and New Orleans began to flood due to levee breaches; later that day, Bush declared a major disaster in Louisiana, officially authorizing FEMA to start using federal funds to assist in the recovery effort. On August 30, DHS Secretary Michael Chertoff declared it "an incident of national significance", triggering the first use of the newly created National Response Plan. Three days later, on September 2, National Guard troops first entered the city of New Orleans. The same day, Bush toured parts of Louisiana, Mississippi, and Alabama and declared that the success of the recovery effort up to that point was "not enough". As the disaster in New Orleans intensified, Bush received widespread criticism for downplaying his administration's role in the inadequate response. Leaders attacked Bush for having appointed incompetent leaders to positions of power at FEMA, notably Michael D. Brown; federal resources to respond were also limited as a result of being allocated to the Iraq War, and Bush himself did not act upon warnings of floods.
Sources: en.wikipedia.org
It is described as a synthetic analogue of the ACTH(4–10) fragment, a short segment of adrenocorticotropic hormone. Its sequence differs from that fragment and includes two proline residues, which influence stability and behaviour in solution.
It appears in Russian pharmaceutical listings as a nasal formulation, but it is not an authorised medicine in the United States or the European Union. Outside those markets it is normally encountered as a research chemical rather than a prescription product.
Laboratory and animal work points to melanocortin signalling and changes in neurotrophic factor levels, especially brain-derived neurotrophic factor. The exact receptor targets and the degree to which these findings transfer to humans are still unresolved.
The main proposal is modulation of neurotrophic factors such as brain-derived neurotrophic factor, supported largely by animal experiments. Receptor-level targets have not been firmly established. Most reviews describe the mechanism as only partially characterized.